Teva 4Q Revenues: $5.2 billion (-8%) 4Q Earnings: $280 million (-44%) FY Revenues: $20.3 billion (+11%) FY Earnings: $1.9 billion (-31%) Comments: Generic revenues in the quarter were $2.7 billion (including API sales of $202 million), down 11%. Specialty medicines revenue was $2.1 billion, down 7%. OTC sales of PGT Healthcare, a joint venture with Procter & Gamble, were $377 million, up 11%. Revenues in the U.S. in the quarter were $2.6 billion (50% of total revenues), down 14% mainly ...